Anamorelin Induced Hyperglycemia in a Patient with Type 1 Diabetes by Stimulating Growth Hormone Secretion

Anamorelin is a selective ghrelin receptor agonist that is used to treat cancer-related cachexia. Ghrelin stimulates growth hormone (GH) secretion. However, the association between anamorelin and hyperglycemia remains unclear. We herein report a case of anamorelin induced hyperglycemia in a patient with type 1 diabetes mellitus. A 67-year-old woman with a history of type 1 diabetes was hospitalized because of a pleural effusion. After hospitalization, the patient was administered anamorelin. Four days after starting anamorelin treatment, her blood glucose and GH levels increased. These results suggest that anamorelin stimulates GH secretion and induces hyperglycemia. Our findings suggest the need to take special care of hyperglycemia when anamorelin is prescribed to patients with type 1 diabetes.